SPECIALIZED PRESS May 29, 2020 Not intended for U.S. and UK Media - American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program):Efficacy of Vitrakvi™ (larotrectinib) further established with continued high response rates and durable response in updated analyses in adult patients and quality of life data in adult and pediatric patients with TRK fusion cancerRead more
May 29, 2020 Bayer furthers commitment to greater transparency on glyphosate and stakeholder engagement through new dialogue event seriesRead more
May 26, 2020 Bayer to support Harvard Research Study to Evaluate Trust in Science, Including in COVID-19 pandemicRead more
SPECIALIZED PRESS May 22, 2020 Not intended for U.S. and UK MediaBayer submits larotrectinib for marketing authorization in Japan for the treatment of TRK fusion cancerRead more
May 19, 2020 Nine internationally recognized experts join Sustainability CouncilIndependent external council to advise Bayer’s Board of Management on consistent implementation of its sustainability targetsRead more
SPECIALIZED PRESS May 14, 2020 Not intended for U.S. and UK MediaBayer and ArcherDX to develop next-generation sequencing (NGS)-based companion diagnostic (CDx) for precision oncology treatment Vitrakvi™Read more
SPECIALIZED PRESS May 13, 2020 Not intended for U.S. and UK Media - New ARAMIS Phase III data to be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific ProgramNubeqa™ (darolutamide) significantly improved overall survival with a favorable safety profile in men with non-metastatic prostate cancerRead more
SPECIALIZED PRESS May 11, 2020 Not intended for U.S. and UK MediaBayer to Present Data from Growing Oncology Portfolio at the ASCO20 Virtual Scientific ProgramRead more
April 28, 2020 CEO Werner Baumann at the Bayer AG Annual Stockholders’ Meeting:“We’re active in the right businesses”Read more
